PCA3 and pachyonychia congenita: As an example, lncRNA prostate cancer antigen 3 (PCA3), which is the most striking example of the use of lncRNA as a non-invasive biomarker in prostate cancer (PC), approved by the FDA (Food and Drug Administration) [15].